Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

BACKGROUND. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs. PATIENTS A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Faggiano, Antongiulio, Malandrino, Pasqualino, Modica, Roberta, Agrimi, Daniela, Aversano, Maurizio, Bassi, Vincenzo, Giordano, Ernesto A., Guarnotta, Valentina, Logoluso, Francesco A., Messina, Erika, Nicastro, Vincenzo, Nuzzo, Vincenzo, Sciaraffia, Marcello, Colao, Annamaria
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2016
Materias:
Endocrinology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943387/
https://ncbi.nlm.nih.gov/pubmed/27053503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0420
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares